Search results
Oxford Nanopore Eyes TB Drug Resistance for First In-House-Developed Diagnostic Test
GenomeWeb News· 3 days agoOxford Nanopore Technologies has been working on a tuberculosis drug resistance sequencing assay that it hopes will become its first in vitro diagnostic ...
ZYMFENTRA™ (infliximab-dyyb) demonstrated long-term efficacy and safety profile of maintenance...
WJET - WFXP Erie· 6 days agoCelltrion USA announced today positive two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) for ZYMFENTRA™ (infliximab-dyyb) in adult patients with moderately to severely ...
Antibiotic resistance causing large avoidable death toll, doctors say
dpa international via Yahoo News· 3 days agoAround 750,000 of the almost 5 million annual deaths caused by antimicrobial resistance - when...
Delhi HC closes PIL on medicine shortage in Rajan Babu Institute after govt's assurance
Investing.com· 4 days agoThe decision came after a division bench of Acting Chief Justice Manmohan and Justice Manmeet PS...
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
Morningstar· 6 days agoTeva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk ...
More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved...
WTRF Wheeling· 6 days agoIn Eli Lilly and Company's (NYSE: LLY) pivotal Phase 3 VIVID-1 study, patients with moderately to severely active Crohn's disease, with or without previous biologic failure, achieved statistically ...
ADA2 regulates inflammation and hematopoietic stem cell emergence via the A2bR pathway in zebrafish...
Nature· 5 days agoA DADA2 zebrafish model with cecr1b deficiency was generated. Characterization of hematopoietic processes revealed a role of Cecr1b in regulating inflammation and hematopoietic stem cell production through the A2br-mediated adenosine signaling.
Over 750,000 antimicrobial resistance deaths preventable yearly via vaccines, water, sanitation and...
Medical Xpress· 3 days agoAuthors say if the world does not prioritize action on AMR now, we will see a steady increase in the...
UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in...
KTLA-TV Los Angeles· 4 days agoUCB, a global biopharmaceutical company, today announced that The Lancet has published results from the Phase 3 BE HEARD I and BE HEARD II trials evaluating the efficacy and safety of BIMZELX ...